Principal Financial Group
VIR icon

Principal Financial Group’s Vir Biotechnology VIR Stock Holding History

Principal Financial Group’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.98M Buy
586,898
+39,145
+7% +$372K ﹤0.01% 1609
2026
Q1 		$4.91M Buy
547,753
+97,158
+22% +$774K ﹤0.01% 1633
2025
Q4 		$2.72M Sell
450,595
-5,105
-1% -$30.4K ﹤0.01% 1786
2025
Q3 		$2.6M Sell
455,700
-3,338
-0.7% -$17.1K ﹤0.01% 1769
2025
Q2 		$2.31M Sell
459,038
-299
-0.1% -$1.6K ﹤0.01% 1780
2025
Q1 		$2.98M Buy
459,337
+12,024
+3% +$107K ﹤0.01% 1688
2024
Q4 		$3.28M Buy
447,313
+15,902
+4% +$125K ﹤0.01% 1704
2024
Q3 		$3.23M Sell
431,411
-3,215
-0.7% -$27.9K ﹤0.01% 1684
2024
Q2 		$3.87M Sell
434,626
-27,404
-6% -$263K ﹤0.01% 1616
2024
Q1 		$4.68M Sell
462,030
-45,597
-9% -$464K ﹤0.01% 1591
2023
Q4 		$5.11M Sell
507,627
-4,065
-0.8% -$37.1K ﹤0.01% 1548
2023
Q3 		$4.79M Buy
511,692
+39,762
+8% +$567K ﹤0.01% 1554
2023
Q2 		$11.6M Sell
471,930
-6,656
-1% -$167K 0.01% 1179
2023
Q1 		$11.1M Sell
478,586
-10,278
-2% -$263K 0.01% 1199
2022
Q4 		$12.4M Buy
488,864
+8,118
+2% +$199K 0.01% 1117
2022
Q3 		$9.27M Buy
480,746
+8,811
+2% +$224K 0.01% 1229
2022
Q2 		$12M Buy
471,935
+445,904
+1,713% +$10.4M 0.01% 1152
2022
Q1 		$670K Buy
26,031
+153
+0.6% +$4.54K ﹤0.01% 2058
2021
Q4 		$1.08M Sell
25,878
-12,562
-33% -$492K ﹤0.01% 1967
2021
Q3 		$1.67M Sell
38,440
-1,118
-3% -$48.4K ﹤0.01% 1902
2021
Q2 		$1.87M Sell
39,558
-540
-1% -$24.6K ﹤0.01% 1929
2021
Q1 		$2.06M Buy
40,098
+287
+0.7% +$15.5K ﹤0.01% 1848
2020
Q4 		$1.07M Buy
39,811
+8,504
+27% +$276K ﹤0.01% 1933
2020
Q3 		$1.07M Sell
31,307
-86
-0.3% -$3.7K ﹤0.01% 1857
2020
Q2 		$1.29M Buy
+31,393
New +$1.05M ﹤0.01% 1777

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Principal Financial Group's VIR Position: Q2 2026 in Review

Principal Financial Group increased its Vir Biotechnology (VIR) stake by 7.1% in Q2 2026, buying an estimated $372K and bringing the position to 586,898 shares worth $5.98M. The position accounts for ﹤0.01% of the portfolio, ranked #1609.

Principal Financial Group first reported a position in VIR in Q2 2020 and has held it in 25 quarters since. The position peaked at $12.4M in Q4 2022. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Principal Financial Group held 586,898 shares of Vir Biotechnology worth $5.98M as of Q2 2026.
  • Principal Financial Group bought 39,145 Vir Biotechnology shares in Q2 2026, an estimated $372K.
  • Vir Biotechnology made up ﹤0.01% of Principal Financial Group's portfolio in Q2 2026, its #1609 holding.
  • Principal Financial Group first reported a position in Vir Biotechnology in Q2 2020 and has held it in 25 quarters since.
  • Principal Financial Group's Vir Biotechnology position peaked at $12.4M in Q4 2022.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Principal Financial Group's 13F filing for Q2 2026, filed 4 Aug 2026.